Tevogen Bio Highlights Proprietary Assets and Upcoming Valuation Disclosure

Core Insights - Tevogen Bio Holdings Inc. has significant internally developed assets that are not reflected on its balance sheet but represent substantial long-term value [1][3] - The company plans to provide detailed information and valuation of these assets in the near future [1] Asset Overview - Key assets include PredicTcell™, which utilizes AI algorithms to predict peptide–T cell receptor interactions, thereby accelerating development and expanding the pipeline [1] - AdapTcell™ employs AI models to decode HLA–T cell interactions, enhancing immune system insights and revealing new therapeutic paths [2] Intellectual Property and Technology - Tevogen holds three granted U.S. patents and has twelve pending U.S. patents, including two related to artificial intelligence [6] - The company has strategic collaborations with Microsoft and Databricks to support its AI technology [6] Drug Development and Clinical Pipeline - The ExacTcell™ platform focuses on highly purified, target-specific CD8+ cytotoxic T lymphocytes (CTL) [6] - The clinical pipeline includes therapeutics designed to treat cancers while allowing patients to continue oncology care, with potential expansion into non-oncology indications [6] Financial Position - Tevogen has access to a line of credit and is well-capitalized for current operations [6] - The company is establishing internal GMP manufacturing capabilities [6] Facilities - Tevogen operates a drug discovery lab in Philadelphia and has its headquarters in New Jersey [6]